SPX3,649.13-5.91 -0.16%
DIA291.54-1.18 -0.40%
IXIC10,824.59+21.67 0.20%

NGM Says NGM120 Shows Signs of Anti-Cancer Activity in Early Stage Trial in Metastatic Pancreatic Cancer

NGM Says NGM120 Shows Signs of Anti-Cancer Activity in Early Stage Trial in Metastatic Pancreatic Cancer

MT Newswires · 09/14/2022 00:17

Please log in to view news